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Abstract 
Exosomes are considered as naturally targeted delivery systems able to carry exogenous 
payloads, drugs or theranostic nanoparticles (NPs). This work aims to combine the 
therapeutic capabilities of hollow gold nanoparticles (HGNs) with the unique tumor 
targeting properties provided by exosomes. Here, we tested different methods to encapsulate 
HGNs (capable of absorbing light in the NIR region for selective thermal ablation) into 
murine melanoma cells derived exosomes (B16-F10-exos), including electroporation, 
passive loading by diffusion, thermal shock, sonication and saponin-assisted loading. These 
methods gave less than satisfactory results: although internalization of relatively large NPs 
into B16-F10-exos was achieved by almost all the physicochemical methods tested, only 
about 15 % of the exosomes were loaded with NPs and several of those processes had a 
negative effect in the morphology and integrity of the loaded exosomes. In a different 
approach, B16-F10 cells were pre-incubated with PEGylated HGNs (PEG-HGNs) in an 
attempt to incorporate the NPs into the exosomal biogenesis pathway. The results were 
highly successful: exosomes recovered from the supernatant of the cell culture showed up to 
50 % of HGN internalization. The obtained hybrid HGN-exosome vectors were 
characterized with a battery of techniques to make sure that internalization of HGNs did not 
affect exosome characteristics compared with other strategies. PEG-HGNs were released 
through the endosomal-exosome biogenesis pathway confirming that the isolated vesicles 
were exosomes. 
Background 
Gold-based NPs are one of the workhorses in Nanomedicine, with applications in widely 
different fields including biosensing,1 drug delivery,2 near-infrared (NIR)-based 
hyperthermia,3 imaging4 and bio-orthogonal catalysis.5 Gold is a suitable candidate for 
those applications due to its low toxicity at the studied doses, inertness and biocompatibility 
compared with other types of materials.6 In addition, nanogold has a wealth of interesting 
properties, among which the “surface plasmon resonance (SPR)” effect is outstanding.7 The 
SPR effect of gold nanoparticles (AuNPs) can be exploited in a wide range of approaches, 
including labelling of living cells,8 imaging,9-11 diagnosis12-14 and therapy.3,15,16 In 
tumor therapy, a variety of strategies have been employed to selectively deliver AuNPs to 
tumors: i) development of an outside layer, typically PEG, that hinders the adsorption of 
proteins and retards detection by the immune system,17 ii) functionalization with targeting 
moieties (such as antibodies, aptamers or internalization peptides)18 and iii) Trojan-Horse 
strategies (i.e. loading the particles inside cell types having tropism towards the desired 
objective).3 Nevertheless, these strategies still present unsolved challenges and the 
preferential accumulation of PEGylated NPs in tumors is very modest.19 
Exosomes are vesicles of endocytic origin from 20 to 200 nm in diameter secreted by the 
majority of the cells present in the organism. They are surrounded by a lipidic membrane 
similar to the plasmatic membrane enriched in lipids such as sphingomyelin, 
phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, ceramide and 
cholesterol.20 Exosomes also contain cytosolic components from the parental cell, including 
mRNA, miRNA, DNA and proteins, which can be horizontally transferred to recipient 
cells.21 These nanovesicles are characterized by the presence of specific proteins, 
independently of the parental cell. In particular, it is well know that the exosome membrane 
contains proteins from a variety of families such as tetraspanines (CD63, CD81 or CD9), 
heat shock proteins (Hsp70), lysosomal proteins (Lamp2b), molecules involved in 
multivesicular bodies (MVBs) biogenesis such as TSG101 and Alix or fusion proteins such 
as flotilin or anexin.22 Exosomes formation is a multistep process that includes i) formation 
of intraluminal vesicles (ILVs) in MVBs, ii) transport of MVBs to the plasma membrane, 
and iii) fusion of MVBs with the cellular membrane.23 Until recently, the primary role 
attributed to exosomes was the elimination of unnecessary or toxic material from cells. 
However, today exosomes are considered as natural signalling vectors that play an essential 
role in intercellular communication processes and in the transfer of small molecules among 
cells.24 Moreover, they have been proposed to be crucial in cancer progression pathways 
(evasion of the immune system, generation of pro-tumoral niches, promotion of angiogenesis 
and tumoral cell proliferation),25 in the development of the nervous system,26 in 
neurodegenerative diseases of the brain27 and in cardiovascular diseases.28 Furthermore, it 
is known that exosomes secrete specific molecules to receptor cells and that they can reach 
different target tissues according to the characteristics of the cells from which they were 
originated, endowing them with exciting possibilities regarding selective targeting.29 In 
view of the above, but especially taking into account the potential targeting capabilities of 
exosomes, it is not surprising that exosomes are emerging as ideal delivery vehicles for 
theranostic applications. A number of attempts have been made to introduce a therapeutic 
payload within exosomes. A decade ago, small lipophilic molecules were passively 
introduced in exosomes by incubation at room temperature.30 Then, more complex 
molecules including anti-oxidants and anti-inflammatory compounds were loaded inside 
them.31-36 The loading of NPs within exosomes is even more challenging due to the large 
dimensions (compared to molecules) and the solid nature of the particles. This means that, 
simple and diffusion-driven methods that rely on the simultaneous incubation of NPs with 
exosomes are hardly used. However, loading NPs into exosomes is highly desirable because 
it combines the attractive features of exosomes as delivery vectors with the unique properties 
of NPs as signalling or therapeutic agents. Therefore, more aggressive physical methods 
have been tested, although still with few successful results. Most of the published works 
have addressed the loading of magnetic NPs within exosomes to provide them with multiple 
capabilities as contrast agents in magnetic resonance imaging (MRI) while serving as drug 
vehicles.37-41 Hood et al., optimized an electroporation procedure to load 5 nm 
superparamagnetic iron oxide nanoparticles (SPIONs) in exosomes while minimizing their 
aggregation.37 A similar strategy was used by Hu et al. to accumulate exosomes loaded with 
SPIONs in the lymphatic nodes using magnetic NPs of 5 nm as contrast agents in MRI.38 
Recently, Qi et al. reported the isolation of serum exosomes by using magnetic NPs of almost 
10 nm functionalized with transferrin.41 In this case the NPs were attached to the external 
surface of exosomes, rather than being loaded inside them. Even fewer studies combine 
exosomes with AuNPs. In 2014, Alhasan et al. incorporated AuNPs of 13 nm of diameter 
conjugated with anti-miRNA21 in human prostate PC-3 cells derived exosomes.42 Betzer et 
al. successfully labelled exosomes with glucose-coated AuNPs (from 5 to 20 nm of 
diameter). They were incorporated on the exosomes assisted by a glucose-dependent active 
mechanism using the resulted hybrid exosomes in non invasive in vivo neuroimaging.43 
Last year, Roma-Rodrigues et al. functionalized AuNPs with thiolated oligonucleotides for 
the selective silencing of an essential gene for the biogenesis and processing of exosomes, 
and thus decreasing exosomal production.44 In spite of those excellent results that show the 
potential of combining exosomes with AuNPs, studies comparing different methodologies 
for an efficient encapsulation of NPs within exosomes are still lacking. Motivated by the 
possibility of using exosomes as tumor-selective carriers for therapeutic AuNPs (capable of 
absorbing light in the NIR for optical hyperthermia therapy), we have attempted the 
encapsulation of entities larger than most of the previously published works (namely 40-45 
nm HGNs) within exosomes by several strategies. Appropriate dimensions of the Au 
nanostructures are key to attaining SPR in the NIR region that can be used for in vivo 
hyperthermia-based treatments.3,45 Herein, different physicochemical methods have been 
tested to load these 40 nm HGNs in exosomes derived from B16-F10 cells. In addition, a 
method involving the direct incubation of cells with HGNs and the subsequent exosome 
collection has also been tested. Remarkably, when exosomes derived from cells incubated 
with HGNs were purified directly from the supernatant fluid, a high yield of exosomes 
loaded with HGNs was obtained. 
Results and discussion 
Characterization of HGNs and B16-F10-exos 
HGNs as well as B16-F10-exos were thoroughly characterized by a battery of 
physicochemical (TEM, DLS and Zeta potential) and biological techniques (WB, Nanosight 
and BCA) detailed in the supplementary material. As previously reported results, Fig. 1 
shows that NPs morphology and properties correspond with the ones described in the 
literature.3,45,46 B16-F10-exos properties were also as the ones reported in previous studies 
(Fig. 2).47,48,49,50  
 
 
Figura 1. HGNs and PEG-HGMs characterization. A) TEM images and size distribution 
histograms (> 200 particles measured) of HGNs (top) and PEG-HGNs (bottom). A 5 nm 
PEG shell can be observed surrounding HGNs after PEGylation when they were stained 
with phosphotungstic acid. B) UV-VIS absorption spectra for both NPs dispersions. 
 
Figura 2. Characterization of B16-F10-exos. A) TEM images of isolated exosomes and size 
distribution histogram obtained from electronic microscopy images. Blue arrow indicates 
the double exosomal membrane. B) NTA measurement of exosomes. C) WB analysis showing 
the expression of two specific exosomal markers (CD9, TSG101) and of one housekeeping 
protein (α-actin) in exosomes. The expression of calnexin was evaluated to confirm the lack 
of expression of a non-exosomal protein. 
 
Physicochemical methods for HGNs loading within exosomes 
Several works reported the encapsulation of therapeutic molecules within exosomes. For 
instance, Zhuang et al. observed that curcumin-loaded exosomes were able to significantly 
reduce lipopolysaccharide-induced brain inflammation in vivo.31 In another study, Haney 
et al. employed ex vivo loading methods for the encapsulation of catalase in macrophage 
derived exosomes. The encapsulation of the enzyme within exosomes preserved its 
enzymatic activity, prolonged blood circulation time and reduced immunogenicity.32 
Herein, HGNs internalization within B16F10-exos was studied using different 
physicochemical methods.  
 
Figura. 3. A) TEM images of exosomes incubated with HGNs and encapsulated using 
different strategies: incubation at room temperature with the presence or absence of 
saponin, two different thermal shock procedures, sonication and electroporation. Blue 
arrows indicate exosomes loaded with HGNs. B) Internalization percentage obtained for the 
different methods.  The amount of HGNs loaded into exosomes varied from 7 % to 19 % and 
increased as follows: electroporation < thermal shock II < incubation at room temperature 
< incubation with saponin < thermal shock II < sonication < Incubation with B16-F10 cells. 
Error bars ± SD, n=3. ****P<0.0001 
 
The obtained HGNs-loaded exosomes by the different strategies were visualized by TEM 
and the percentage of loaded exosomes was estimated from the electronic microscopy 
images (Fig. 3A). The semiquantive analysis of the encapsulation efficiency achieved by the 
different approaches is shown in Fig. 3B. As the role of saponin as an effective detergent is 
well known,51 it was incorporated into the HGNs together with the exosome-based 
suspension to facilitate pore opening in the exosomal membrane favouring HGNs 
encapsulation. The encapsulation yield increased somewhat from 13.7 ± 9.9 % to 16.4 ± 5.1 
% when saponin was added to the mixture compared to the situation when HGNs were 
allowed to passively diffuse inside exosomes. Fig. S1 indicates that neither the passive 
incubation of HGNs with exosomes at room temperature, nor the use of saponin affected 
exosome morphology. However due to the relatively low encapsulation yields achieved 
when saponin was added, and to the concerns regarding to its haemolytic function, the use 
of this permeabilizer would be limited in vivo.52 
Encapsulation yields of 18.20 ± 1.35 % and 9.11 ± 2.0 % were respectively obtained when 
thermal shocks I and II were applied. Differences on the incorporation yields obtained 
between the two thermal methods might be due to the temperatures reaches and the pore 
sizes obtained with them. While freezing down at -80 ºC (thermal shock I) might disrupt 
permanently the exosomal membrane, thermal shock II might produce smaller and temporal 
pores. Haney et al, already used thermal shock I to include catalase on the exosomes32  but 
the size and type of compound (drug, nanoparticle etc) and the hole size would be important 
for their incorporation inside the vesicles. Herein, not only low encapsulation yields of 
HGNs were obtained but also the process affected exosomal morphology and induced 
aggregation. As the exosomes morphology was not affected by both thermal shock strategies 
in absence of NPs (Fig. S1), we attributed the exosome damage to the massive deformation 
that their membranes undergo when they incorporated HGNs inside their compartment 
following this thermal route. In fact, it is described that freeze and thaw cycles on exosomes 
in the presence of some drugs can induce their rupture and their aggregation.32  
Similar to whole cells, Kim et al., have shown that when suing sonication, exosome 
membrane viscosity significantly decreases.53 Thus, sonication could create holes/pores in 
the exosomal lipid bilayer promoting NPs incorporation. In fact, Haney et al., reported the 
internalization of catalase within exosomes using ultrasounds.32 Interestingly, our results 
showed that mild sonication treatment increased the loading yield compared with the 
previous methods (19.34 ± 10 %) and TEM images also suggest that the effect of this process 
on exosome morphology was minimal (Fig. 3). In fact, it seems to be more effective than the 
previous methods: the loading yield obtained was the highest of the different 
physicochemical approaches employed. We hypothesize that when submitting exosomes to 
mild sonication, a reorganization and reshaping of their membrane take place, and the 
presence of HGNs in the vicinity leads to a large number of encapsulation events.54 
Nevertheless, TEM images revealed that some NPs were attached to exosomal membrane 
rather than being inside them. In fact, it is reported that sonication could promote the 
attachment of drugs to the outer layer of membranes when the membrane reorganization 
process takes place.53 
Electroporation has been used for the encapsulation of nucleic acids into exosomes. For 
instance, Alvarez-Erviti et al. used electroporation to introduce siRNAs in exosomes for the 
treatment of Alzheimer disease.33 Electroporation of exosomes was also employed by Ohno 
et al. to load miRNA to inhibit the expression of epidermal growth factors in human breast 
cancer cells.34 This technique disturbs the exosomal membrane opening temporary pores in 
the presence of an electrical field in a conductive solution.55 In our study, electroporation 
seems to cause unacceptable damage to exosomes (TEM images shown in Fig. 3 of 
electroporated exosomes in the presence of HGNs revealed significant effects on exosomes 
morphology and the formation of large organic aggregates). In fact, exosome electroporation 
procedure by itself was extremely harmful for the exosome integrity (Fig. S1).  
In summary, with the methods reported so far, no statistical differences were obtained among  
mild sonication, thermal shock I, thermal shock II and incubation at RT with or without 
saponin. On the contrary, significant differences were observed between these approaches 
compared with electroporation. Electroporated exosomes in the presence of HGNs showed 
not only very low encapsulation yields but also significant effects on exosomes morphology 
and large aggregates were observed, evidencing that this method was extremely harmful for 
the exosome integrity. The statistical analysis is detailed in the supplementary material.  
The NPs encapsulation efficiencies herein obtained were comparable (and sometimes better) 
than those showed in previous reports for smaller molecules and drugs. Yang et al. reported 
a drug loading yield of 7.2 % and 11.7 % for placitaxel (PTX) and doxorubicin (DOX) 
respectively, by incubation at room temperature.36 Also, Raposo et al. tested different 
procedures for the encapsulation of catalase in exosomes obtaining loading yields from 20 
% to 26 %.22 Finally, Kim et al., incorporated PTX into exosomes and the amount of the 
chemotherapeutic agent increased as follows: incubation at RT < electroporation < 
sonication.53  
Due to the low encapsulation efficiencies obtained by the physicochemical approaches, we 
decided to use the cellular machinery to encapsulate the NPs inside exosomes. We initially 
tested the cytotoxicity of the PEG-HGNs in B16-F10 cells in order to obtain the HGNs 
subcytotoxic dose to achieve their encapsulation into exosomes following the biogenesis 
pathway of the cells without causing cytotoxic effects.   
 
Cytotoxicity evaluation 
The Blue Cell Viability assay (Fig. 4A) revealed that PEG-HGNs did not significantly affect 
cell viability at any of the studied doses in the time intervals tested. These results are in 
agreement with other works developed in our laboratory with the same particles.46 
Nevertheless, when B16-F10 cells were incubated with HGNs a decrease on cell viability 
could be observed for the highest doses (0.5 mg mL-1). This is in contrast with PEG-HGNs 
treatment, whose cell viability was not significantly changed when time increased. 
According to the ISO 10993-5 (Biological evaluation of medical devices. Part 5: Test for in 
vitro cytotoxicity) a reduction in cell viability higher than 30 % compared to the control is 
considered as a cytotoxic effect. Consequently, 0.125 mg mL-1 was chosen as a subcytotoxic 
dose for HGNs and PEGylated HGNs for the following experiments.  
 
 
Figura 4. A) Viability of B16-F10 cells treated with HGNs and PEG-HGNs during 24, 48 
and 72 h. B) Confocal images of B16-F10 cells incubated without treatment (control), with 
HGNs or PEG-HGNs. Green channel corresponds with actin filaments labelled with 488-
phaloidin, blue channel show nuclei stained with Draq5 and pink channel indicates 
reflection from nanoparticle agglomerates. Orthogonal projections reveal pink spots of 
agglomerated HGNs and PEG-HGNs inside cell cytoplasm. C) Gold content (mg/cell) 
obtained from by MP-AES analysis of cell cultures after removing non-internalized NPs at 
24, 48 and 72 h. Error bars ± SD, n=3. **P<0.01, ***P<0.001, ****P<0.0001 
Incorporation of PEG-HGNs in the exosome biogenesis pathway: pre-incubation with 
B16-F10 cells  
Although some of the physicochemical approaches tested (mild sonication and thermal 
shock I) gave satisfactory results, we decided to test an alternative method in which the 
incorporation of NPs to exosomes would take place using the own cellular biogenesis 
mechanism. This had not been attempted before with therapeutic NPs capable of absorbing 
light in the NIR. Before harvesting any PEG-HGNs loaded exosomes (hereinafter termed 
exosPEG-HGNs), we studied the internalization of both HGNs and PEG-HGNs within B16-
F10 cells at different time points in order to find out the optimum configuration (with or 
without PEG coating) and the best incubation time to purify the final exosomes loaded with 
the NPs. Confocal microscopy, (Fig. 4B) revealed that, as expected from their large size, 
both kind of NPs were distributed in the cytoplasm rather than in the nuclei after 24 h of 
internalization. The amount of gold inside B16-F10 cells was quantified by Microwave 
Plasma-Atomic Emission Spectrometry (MP-AES) of the cellular pellet retrieved after 
incubation of the cells with AuNPs at different times (24 to 72 h) and washing them to 
remove the supernatant fluid with any non-internalized NP (Fig. 4C). Both MP-AES results 
and confocal microscopy revealed that a more intense uptake of PEG-HGNs by B16-F10 
cells compared to HGNs occurred at any of the times tested under the conditions used (Fig. 
4B and 4 C). In particular, Fig. 4C indicates that an average uptake of 0.14 ng of Au per cell 
was measured when PEG-HGNs were incubated for 24 h (corresponding to more than 
600000 PEG-HGNs per cell). The higher internalization of PEG-coated particles compared 
to their uncoated counterparts has been reported previously for different cell lines (MSCs or 
tumoral cells) and attributed to a facilitated uptake thanks to the increase of NPs stability and 
reduced agglomeration provided by the PEG coating.45,46 
Considering the data provided by the internalization studies, we incubated cells with PEG-
HGNs during 24 hours in order to obtain exosPEG-HGNs. We carried out electronic 
microscopy studies to evaluate the presence or absence of NPs inside exosomes after their 
purification from B16-F10 cell cultures (Fig. 5). TEM images of purified exosPEG-HGNs 
show that a large proportion of exosomes secreted by parental cells were loaded with NPs 
(statistical analysis shown in Fig. 3B indicated that 49.11 % of exosomes were loaded with 
AuNPs). 
 
Figure 5. Representative TEM images obtained from exosomes released by B16-F10 after 
their incubation with PEG-HGNs during 24 hours. 
 
To confirm that PEG-HGNs were inside exosomes and not attached to their surface, we 
carried out confocal microscopy studies to evaluate the co-localization between PEG-HGNs 
and B16-F10-exos. On the one hand, as a negative control, we added separately prepared 
NPs to a suspension of exosomes in PBS and they were directly observed under confocal 
microscopy. As Fig. 6A shows, segregated red spots (corresponding to reflection from 
aggregates of PEG-HGNs) and green spots (pertaining to exosomes labelled with PKH67 
probe) were observed, with no apparent co-localization. On the other hand, when exosPEG-
HGNs purified from parental cells were visualized under confocal microscopy, yellow pixels 
could be observed, corresponding to the co-localization of the red spots from PEG-HGNs-
based agglomerates reflection and the green fluorescence from exosomes.  
 
Figure 6. A) Co-localization study by confocal microscopy. Nanoparticle-based 
agglomerates were directly observed by reflection (red spots), and exosomes were labelled 
with PKH67 probe (green spots). Yellow pixels correspond with co-localization of exosomes 
and NPs. B) DLS measurements obtained of exosomes control and exosPEG-HGNs. C) 
Analysis of CD9 and α-actin expression of empty and loaded exosomes by WB. D) Agarose 
retention assay for control (i.e. free from HGN inclusions) exosomes and exosPEG-HGNs. 
E) NTA diameter distribution obtained for exosPEG-HGNs. 
 
A WB test of control exosomes and exosPEG-HGNs isolated from the same number of 
parental cells is shown in Fig. 6C. Clearly, specific exosomes proteins (CD9) were expressed 
in exosPEG-HGNs, confirming the exosomal nature of exosPEG-HGNs. Also, for the same 
number of secreting cells the expression levels of CD9 increased when PEG-HGNs were 
present, suggesting that PEG-HGNs could stimulate exosomal secretion. Similarly, 
expression of α-actin (control protein) was elevated in exosomes secreted by B16-F10 cells 
exposed to PEG-HGNs. Additionally, control (HGN-free) exosomes and exosPEG-HGNs 
were subjected to an agarose retention assay. As it is well known that exosomes carry DNA 
with a large size (> 2.5 kbp),56 after the formation of the complex exosome-nanoparticle the 
exosomal DNA gets retained in the well, as shown in  Fig. 6D. The differences in migration 
rates cannot be explained by a larger size of the exosomes (mean diameters of empty or 
loaded exosomes obtained by NTA were similar, Fig. 2B and Fig. 6E, respectively) or by a 
change in their surface charge since, as shown in TEM and NTA results the diameter and the 
surface charge (-18.56 ± 1.93 mV vs -19.5 ± 1.2 mV) of exosPEG-HGNs and control 
exosomes were rather similar. Betzer et al., observed that zeta potential of exosomes became 
slightly more negative due to the attachment of AuNPs to their surfaces.43 In our study, 
surface charge of exosome was not changed by the presence of the NPs confirming again the 
presence of the NPs inside the exosomes.  
Only few studies have attempted the encapsulation of NPs within exosomes and most of 
them employ exogenous methods to achieve relatively low encapsulation efficiencies (table 
1). The majority of the previous works tried to encapsulate SPIONs within exosomes by 
electroporation for MRI and tracking applications.37,38 Rather than encapsulating SPIONs, 
Qi et al. created a dual-functional exosome-based cluster by anchoring SPIONs on exosome 
surface through Tf-Tf receptor interaction for cancer therapy.41 However, to the best of our 
knowledge only three studies reported the encapsulation of AuNPs in exosomes. Alhasan et 
al. treated parental PC-3 cells with AuNPs of 13 nm conjugated to anti-miRNA21 to purify 
their exosomes.42 They observed that AuNPs were both localized inside exosomes and 
attached to their surface. In a different approach, Betzer et al. loaded exosomes with glucose-
coated AuNPs from 5 to 20 nm in diameter. Although most of the AuNPs were successfully 
loaded within exosomes, few of them remained attached on the exosome surface.43 Finally, 
Roma-Rodrigues et al. functionalized AuNPs with thiolated oligonucleotides and incubated 
them with MCF-7 cells. Subsequently, they observed that 30 % of the exosomes purified 
from parental cells were associated with AuNPs. They also incubated exosomes with AuNPs 
for 24 h achieving less than 5 % of encapsulation.44  
The manipulation processes involved in those previous strategies decrease safety and 
increase the cost. Herein, we report a simple strategy to effectively load therapeutic PEG-
HGNs that absorb in the NIR region onto exosomes avoiding difficult or aggressive 
treatments (such as membrane disruption) or any chemical bonding on the exosomal 
membrane wall to preserve the natural characteristics of the produced exosomes. We have 
improved the encapsulation yield from 20 % to 50 % when parental cells were pre-treated 
with NPs before exosomes isolation. As previously shown, TEM and NTA results indicate 
that this loading approach is likely to preserve the natural size of the produced exosomes. 
We demonstrated the presence of AuNPs inside exosomes instead of attached to their 
surfaces using confocal microscopy co-localization assays and by zeta potential studies.  
 
PEG-HGNs are released through the exosomal secretory route 
To confirm that exosPEG-HGNs were in fact exosomes rather than other membrane derived 
vesicles, the implication of exosome biogenesis and release pathways in the exosPEG-HGNs 
production was evaluated. B16-F10 cells were pre-treated either with manumycin A or 
transfected with siRab27 to inhibit the budding of intraluminal vesicles into MVBs of the 
PEG-HGNs and to block the late steps of vesicle exocytosis in cells.57,58 Our results 
demonstrate that when exosome biogenesis of the B16-F10 cells was inhibited, the number 
of released exosPEG-HGNs was significantly lower. This fact, together with the previous 
characterization results, confirmed that exosPEG-HGNs were from endosomal origin. 
Exosome production was quantified by WB (Fig. 7) demonstrating that Tsg101 expression 
was lower after exosome genetic or chemical blockade in comparison with the level obtained 
for control B16-F10 cells. Again, Fig. S2 shows TEM images of both control and exosPEG-
HGNs purified from manumycin A and siRab27 treated cells. It clearly demonstrated that 
the number of exosomes produced by the untreated cells were significantly more abundant 
than the exosomes produced by the treated cells. 
 
Figure 7. Characterization of exosomes produced by siRab27 and manumycin A treated 
cells. WB of calnexin (non-exosomal marker) and Tsg101 (specific exosome marker) of 
cellular and exosomal fractions. Images were analyzed using ImageJ software and 
quantified as a fold increase compared to untreated cell-derived exosomes. 
 
Theranostic properties of exosPEG-HGNs 
The combination of exosomes with NPs and in particular with gold nanoparticles as vectors 
for therapy and imaging of different physiological or pathological conditions has been 
described before. For instance, the use of the exosome-nanoparticles as a theranostic 
platforms is highlighted by Zhu et al. In fact, they established that exosomes play a crucial 
role in the NPs-induced system immune response by promoting the activation of the innate 
immune system (i.e., T-cells) and the maturation and differentiation of the dendritic cells.59 
As a result, they took advantage of this phenomenon to develop a dual vaccine based on 
dendritic cells-derived exosomes against melanoma and lung tumors. The vesicle-based 
vaccine stimulated T lymphocytes and caused tumor rejection providing a highly effective 
and cell-free antitumor therapy based on exosomes.60 
Herein, in vitro optical hyperthermia experiments were performed to demonstrate the 
therapeutic potential of exosPEG-HGNs. The in vitro photothermal effect was analysed 
using 10 µg of exosPEG-HGNs on B16-F10 cells. Figure 8A demonstrates that exosPEG-
HGNs were able to generate localized heat by the use of NIR light. Specifically, after 25 
minutes of NIR laser exposure, a temperature increment in the culture media of 10.93 +/- 2.5 
ºC and 6.5 +/- 1.21 ºC were caused by the presence and absence of exosPEG-HGNs 
respectively. Similarly, the temperature increased 12.13 +1.78 ºC and 6.87 +/- 1.59 ºC in 
cultures incubated with or without exosPEG-HGNs after 30 minutes of NIR laser irradiation. 
Furthermore, Figure 8B reveals that 808 nm irradiation did not reduce cell viability 
(measured by fluorescence microscopy) on cells treated with the laser without the exosPEG-
HGNs. On the contrary, the heat transmitted by this novel NIR-absorbing vector upon laser 
irradiation lead to tumor cell death in a cell culture in the presence of exosPEG-HGNs (a 
hole in the center of the well plate where the laser was applied was observed, corresponding 
with dead cells).  
 
Table 1. Strategies previously reported for the NPs encapsulation within exosomes 
 
Related to the diagnostic/imaging potential of the vector, the inherent reflective optical 
properties of the exosPEG-HGNs allowed us to directly visualize clusters of exosPEG-
HGNs inside of the cells by reflection of the incident light from the confocal microscope at 
488/490 nm ex/em (Figure 8C). Representative images from B16-F10 cells incubated with 
exosPEG-HGNs for 2, 4, 6, 8, 24 and 32 h clearly demonstrates the presence of exosPEG-
HGNs inside cell cytosol and highlights the potential use of this vector for in vitro cell 
labeling. Furthermore, the presence of the exosPEG-HGNs was semiquantified from 
confocal images. Figure 8D reveals that the presence of exosPEG-HGNs significantly 
increased inside the cells after 6 h of incubation and thus, the imaging properties of the 
exosomal vector. 
 
Figure 8. A) Temperature increase of cell culture after NIR laser irradiation in the presence 
or absence of exosPEG-HGNs. B) LIVE/DEAD images of B16-F10 irradiated or non 
irradiated and/or  treated with exosPEG-HGNs. C) Merged confocal images of B16-F10 
cells after treatment with exosPEG-HGNs for 2, 4, 6, 8, 24 and 32 h. Actin fibers (phalloidin-
488) are shown in green, cell nuclei (Draq5) in blue and clusters of exosPEG-HGNs in red. 
D) Quantitative analysis of red fluorescent intensity in the cells at different timepoints. Error 
bars ± SD, n=3. ***P<0.001, ****P<0.0001. 
Materials and methods  
Physicochemical methods for HGNs loading within exosomes 
AuNPs synthesis and exosome purification techniques are thoroughly described in the 
supplementary material section. All the physicochemical and biological techniques 
employed for NPs and vesicles characterization are also detailed in the supplementary 
material. HGNs internalization within B16-F10-exos was studied using different 
physicochemical methods. In all cases, exosomes were previously purified and then mixed 
with NPs. In a final volume of 200 µL of PBS, 10 µg of B16-F10-exos and 33 µg of HGNs 
were put in contact and subjected to the processes described below. The methods were also 
applied to exosomes in the absence of NPs, to find out how all the employed techniques 
affected exosomes morphology. The encapsulation was defined as the percentage of 
exosomes containing NPs. The physicochemical strategies for NPs loading within exosomes 
were performed in triplicate.  
 
PEG-HGNs preincubation in B16-F10 cells and exosPEG-HGNs isolation 
Herein we developed an approach of exosome loading by incubating parental cells (B16-F10 
cells) with HGNs or PEG-HGNs at subcytotoxic dose (see supplementary information) 
followed by isolation of the secreted PEG-HGNs loaded exosomes (exosPEG-HGNs) from 
the conditioned media. To develop an optimum procedure, we firstly evaluated the amount 
of NPs within cells at different time-points in order to choose the maximum internalization 
time for the isolation of exosPEG-HGNs. PEG-HGNs internalization within B16-F10 cells 
was evaluated by confocal microscopy and was quantified by MP-AES. Both procedures are 
detailed in the supplementary information section. 
It is reported that parental cells can be loaded with exogenous compounds, which are then 
released into the conditioned media within exosomes.61 To obtain exosPEG-HGNs directly 
from cell cultures, NPs were added to ULTRACEN medium at the subcytotoxic dose (0.125 
mg mL-1). B16-F10 cells were cultured with this enriched medium for 24 h, allowing 
particles to be uptaken and incorporated into the biogenesis exosome pathway. Then, cells 
were strongly washed three times wih PBS to discard the non-internalized PEG-HGNs. 
Finally, the culture media was replaced by exosome-free medium during 48 h and the 
exosomes excreted during this period were purified from the supernatant by using 
ultracentrifugation cycles (described in the supplementary material section). The presence 
of PEG-HGNs in exosomes was analyzed by: TEM, co-localization with confocal 
microscopy, WB, Nanosight, Zeta potential and agarose gel electrophoresis retention assays. 
For TEM analysis, isolated PEG-HGNs-exos were deposited on Formvar carbon-coated 
grids to be further stained with phosphotungstic acid (3 %) and visualized as mentioned in 
the supplementary information section. In order to estimate the encapsulation efficiency, the 
number of exosomes loaded with at least one PEG-HGNs presented in TEM images were 
quantified and normalized by the total amount of exosomes presented in the sample. The 
experiments were performed at least in triplicate from independent cell cultures of B16-F10 
cells.   
For the co-localization studies, exosomes were labelled with PKH67 probe (Sigma-Aldrich, 
United States) as indicated by the manufacturer and PEG-HGNs were directly visualized by 
reflection. Samples were then visualized by confocal laser scanning microscopy in a µ-Slide 
8 Well (Ibidi, Germany) dissolved in PBS in 300 µL of final volume (Spectral Confocal 
Microscope Leica TCA SP2). CD9 and α-actin expression of control exosomes and 
exosPEG-HGNs were evaluated by WB as mentioned in the supplementary information 
section. Thakur et al., have previously reported that tumor derived exosomes carry double 
stranded DNA (dsDNA) larger than 2.5 kb associated with the outer membrane of 
exosomes.56 Thus, the PEG-HGNs loading within exosomes was also evaluated by 
detecting dsDNA of exosomes on an agarose gel electrophoresis retention assay. The loading 
buffer was mixed with the complexes before adding them into 1 % of agarose gel containing 
SYBER® Safe stain (Life Technologies, United States). After running the gel at 150 V for 
45 min, the migration of exosomal DNA was visualized in a UV chamber (Biorad ChemiDoc 
RXS, Unites States). The full procedures of Zeta potential and Nanosight measurements are 
shown in the supplementary information section.  
 
Theranostic properties of exosPEG-HGNs 
B16-F10 cells were cultured at a cell density of 1.5 x 104 cells per well in a 48-well plate 
for 24 h. Then, culture media was removed and 10 µg of exosPEG-HGNs were added to the 
cells and the samples were irradiated with the NIR diode laser (808 nm, for 30 min at 1.5 
kW cm-2). After that, cells were incubated with the LIVE/DEAD kit (ThermoFisher, United 
States) following manufacturer instructions and they were visualized under an inverted 
fluorescence microscope (Olympus IX81) performing a multi-alignment of 4x images to 
visualized the whole well. Control samples (not irradiated and/or not treated with exosPEG-
HGNs) were also evaluated to obtain the basal viability status of the cells.  
B16-F10 cells were also seeded at a density of 2.5 x 104 cells per well onto 20 mm cover 
slips (in a 24-well plate) and incubated under culture conditions for 1 day. 10 µg of exosPEG-
HGNs were then added to each well and they were incubated for 2, 4, 6, 8 and 24 h. Cells 
were finally fixed, stained and visualized by confocal microscopy as mentioned in the 
supplementary information. Z-stack orthogonal projections were used to visualize the 
presence of exosomes inside cell cytosol.  
Conclusions 
The strategy herein developed proved to be highly efficient (around 50 % encapsulation 
yield) to achieve the encapsulation into exosomes of plasmonic nanoparticles used in 
photothermal ablation (i.e., 45 nm PEG-HGNs). The protocol did not significantly alter their 
structure, morphology or expression of exosomal proteins. Interestingly, the PEG coating 
was key to the success of this procedure: internalization of uncoated HGNs was considerably 
less effective and therefore those NPs could not be incorporated in significant proportions 
into the exosome generation pathway.  
The complexes exosPEG-HGNs open the possibility to be used as theranostic vectors, as 
they are susceptible of producing extensive cell death upon NIR irradiation and of being 
visualized due to their inherent reflective optical properties. Given the outstanding properties 
of exosomes for stealth transport and cell targeting, the encapsulation of NIR-activable NPs 
opens up exciting possibilities in phototherapy. 
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1. Materials and methods 
1.1. Synthesis and characterization of HGNs 
All chemicals used in the HGNs synthesis were obtained from Sigma-Aldrich: cobalt (II) 
chloride hexahydrate, sodium citrate tribasic dehydrate, poly (vinylpyrrolidone) (PVP) 
Mw=55000 Da, gold (III) chloride hydrate (50 % purity), sodium borohydride, and poly 
(ethylene glycol)-ether thiol (PEG 1000 Da Mw). HGNs synthesis was scaled from the 
previously reported protocol reported by Preciado-Flores et al.1 The resulted HGNs were 
functionalized with monofunctional poly (ethylene glycol)-ether thiol (PEG 1000 Da Mw). 
After and before the PEGylation step, NPs were characterized by transmission electron 
microscopy (T20-FEI Tecnai transmission electron microscopy (TEM)), UV-VIS 
spectroscopy and measurement of surface charge. ImageJ software (NIH-RSB) was 
employed to determine the average particle diameter of both HGNs and PEG-HGNs, 
measuring a minimum of 200 particles.  
1.2. Cell culture conditions 
Metastatic murine skin melanoma cells were provided by cell services from Cancer 
Research-UK and cultured in Dubecco’s modified Eagle’s medium (DMEM; Biowest, 
France) supplemented with 10 % FBS (GIBCO, United States), 1 % penicillin/streptomycin 
and 1 % amphotericin (Biowest, France), under normoxic conditions. Ultracentrifugated 
(ULTRACEN medium, 100000 g, 8 h, 4 ºC) serum was used in order to guarantee exosomes 
free medium.   
1.3. Exosome isolation and characterization 
B16-F10-exos were isolated following a protocol previously developed in our lab and based 
on successive ultracentrifugation cycles from cell culture supernatants2. First of all, cells 
were cultured until confluence. In the first step, supernatants were collected and were 
 
centrifuged for 20 min at 2000 g at 4 ºC. Secondly, another centrifugation step was carried 
out for 1 h at 10000 g at 4 ºC to eliminate the microvesicles.  To obtain the exosomal fraction, 
the samples were ultracentrifuged for 2 h at 100000 g at 4 ºC. However, another 
ultracentrifugation step in the same conditions was necessary in order to eliminate the 
surrounded proteins of the exosome.  The obtained precipitates were resuspended in PBS 
and a Pierce BCA protein assay (Thermo Fisher Scientific, United States) was performed in 
order to estimate the protein content in the exosomes sample. B16-F10-exos size, shape and 
morphology were characterized by TEM by contrasting them with phosphotungstic acid (3 
%). From TEM images, the average diameter of exosomes was obtained using ImageJ 
software (NIH-RSB). The surface charge of exosomes was also determined at pH= 7 in PBS 
(Brookhaven 90 plus and ZetaPALS software). To identify specific surface proteins such as 
CD9, western blotting was carried out.  Briefly, 25 µg of B16-F10-exos were precipitated 
with acetone (1:1 w/w), lysed in Laemmli buffer (Sigma-Aldrich, United States) and boiled 
at 95 ºC during 5 min.  Subsequently, proteins were separated by 12 % SDS-polyacrylamide 
gel electrophoresis during 2 h and transferred to nitrocellulose membranes at 4ºC during 4 
h. The membranes were blocked overnight with non-fat dry milk in tris-buffered saline 
(TBS) 5 %. After that, blots were incubated with primary antibodies CD9, 1:2000 (Abcam, 
United Kingdom), TSG101, 1:500 (Abcam, United Kingdom), calnexin, 1:1000 (Abcam, 
United Kingdom) and α-actin, 1:10000 (Sigma-Aldrich, United States). Membranes were 
washed three times with TBS-Tween (TBST) followed by the incubation of the secondary 
antibody (Sigma-Aldrich, United States). Finally, membranes were extensively washed and 
after the addition of chemiluminescence substrate, imaging was carried out. Cellular lysates 
from parental cells were used as negative control. Size distribution of exosomes was 
measured using Nanosight (Malvern Instruments, United Kingdom). Samples were diluted 
 
in PBS to optimize the number of particles in the field of view. They were measured at room 
temperature in triplicate for 60 seconds. 
1.4. Physicochemical methods for HGNs-loaded exosomes 
HGNs internalization within B16-F10-exos was studied using different physicochemical 
methods.  
Incubation at room temperature.  HGNs internalization within exosomes at room 
temperature was performed by mixing them during 18 h without stirring. 
Incubation at room temperature with saponin. It is well known that saponin selectively 
interacts with membrane cholesterol molecules, forming pores and/or removing cholesterols 
from the cell membrane.3 Once B16-F10-exos were mixed with HGNs, saponin was added 
at 0.2 % and the sample was mixed under stirring during 20 min at room temperature. 
Thermal shock I. In this method, the exosome-NPs mixture was frozen at –80 ºC during 30 
min and subsequently allowed to defrost. This freeze-thaw cycle was developed three times.  
Thermal shock II. A classical strategy for bacterial transformation was applied to the 
encapsulation of HGNs within exosomes4. In this case, the sample was heated at 42 ºC for 
30 seconds, followed by incubating it at 4 ºC during 2 minutes.  
Sonication. The sonication conditions employed in this method were adapted from Haney et 
al., employing ultrasounds higher than 20 KHz to generate transitory pores in exosomal 
membranes.5 Exosome-NP mixture was sonicated (UW 2200 Bandelin Sonopuls, Germany) 
in an ice bath at 500 V, 2 kHz during 6 cycles (4 seconds of pulse and 2 seconds of pause). 
Electroporation. The conditions previously developed by Hu et al. for the electroporation of 
exosomes to introduce SPIONs were employed when following this method.6 Briefly, 
 
suspended exosomes were electroporated in the presence of HGNs (Genepulser Xcell 
electroporator, Biorad, United Kingdom) in 4 mm path length electroporation cuvette. A 
single pulse was applied under a 950 µF of capacitance and infinite resistance. 
1.5. Cytotoxicity evaluation 
To determine cell viability of B16-F10 cells under the effect of HGNs and PEG-HGNs, the 
Blue Cell Viability assay® (Promega, United States) was employed as previously reported.7 
The experiment was performed in triplicate. 
1.6. PEG-HGNs preincubation in B16-F10 cells and exosPEG-HGNs isolation 
The cellular uptake was observed under a confocal microscope (Spectral Confocal 
Microscope Leica TCA SP2 and ZEISS LSM880 Confocal Laser Scanning Microscope) 
with a 63x oil immersed N.A. 1.40 objective. Cells were seeded at a density of 2·104 cells 
onto 20 mm cover slips (in a 24-well plate) and cultured for 24 h. The NPs (0.125 mg mL-
1) resuspended in DMEM were added to the cells and incubated for 24 h. Then, cells were 
fixed with para-formaldehyde (PFA) 4 %. Cytoplasmic actin was labeled by staining with 
phalloidin-Alexa488 (Invitrogen, United States) and Draq-5 was used to observe the nuclei. 
Reflection of the incident light at 488/490 nm was used to directly visualized HGNs and 
PEG-HGNs-based agglomerates. Z-stack orthogonal projections were analyzed to determine 
the presence of NPs inside the cytosol.  
Finally, to quantify the amount of gold inside B16-F10 cells, they were seeded onto 6-well 
plates at a density of 2.5 x 105 cells per well and were grown for 24 h. Later, HGNs and 
PEG-HGNs dispersions (0.125 mg mL-1) were prepared in fresh DMEM and added to the 
cell cultures for 24, 48 and 72 h. After these time points, cells were harvested and washed 
twice with PBS (1500 rpm, 5 min). Control samples (cells without treatment) were collected 
using the same protocol. The cellular pellets obtained were digested with 10 % Aqua regia 
 
(HNO3 + 3HCl) in 1.5 mL of dH2O. Digestion was performed at room temperature for 1 h. 
Total amount of gold derived from HGNs and PEG-HGNs was determined by MP-AES 
(4100 MP-AES, Agilent Technologies, United States). Furthermore, considering NPs as 
hollow spheres of known diameter and thickness and knowing gold metal density, the gold 
mass present in each particle (HGH and PEG-HGN) could be estimated, and from this, the 
number of NPs per cell at 24, 48 and 72 h was calculated after allowing for the contribution 
of PEG mass, obtained from the thermogravimetric analysis (TGA).6 
1.7.PEG-HGNs are released through the exosomal secretory route 
To evaluate the exosome biogenesis and release pathways, 2 x 105 cells per well were seeded 
onto a 6-well plate and were grown for 24 hours in complete DMEM medium. Then PEG-
HGNs were added at 0.125 mg mL-1 to the cell cultures for another 24 hours. Before 
purifying exosPEG-HGNs, B16-F10 cells were treated during 2 hours with 2 µM 
manumycin A (Sigma-Aldrich, United States) in order to suppress exosome secretion. It is 
reported that manumycin A inhibits endocytosis via inhibition of Ras signaling in cancer 
cells.57 Separately, cells were transfected with 250 nM ON-TARGET plus mouse Rab27a 
siRNA-SMART pool (Dharmacon, United States) using Lipofectamine 2000 
(ThermoFisher, United States). Rab27 is a GTPase that mediates the late steps of vesicle 
exocytosis in cells.58 Thereafter, DMEM medium was replaced by ULTRACEN medium 
during 48 h for the subsequent exosome isolation procedure. In order to compare the number 
of exosomes secreted when cells were treated with manumycin A or when they were 
transfected with Rab27-siRNA, exosPEG-HGNs produced by untreated B16-F10 cells were 
considered as controls. ExosPEG-HGNs isolated from the different treated cells, were 
characterized by TEM, WB and BCA as previously described the exosome isolation and 
characterization section. From TEM images a semiquantitative analysis was performed in 
 
order to estimate the number of empty or loaded exosomes produced by treated cells 
compared with the control cells.  In WB, calnexin and TSG101 expression were analysed as 
shown in the supplementary information section. 
1.8. Statistical analysis 
All the results expressed as the mean ± the standard deviation were performed in triplicate. 
The statistical analysis of the data was carried out using the GraphPad Prism 7.04. 
Significance was determined by one-way analysis of variance (ANOVA) using the Tukey’s 
multiple comparisons test for the encapsulation strategies, cytotoxicity and MP-AES results 
and the Dunnett’s multiple comparison test for the MP-AES data: *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. 
2. Results and discussion 
Physicochemical characterization of HGNs 
Both HGNs showed a diameter of 36.3 ± 5.4 nm and PEG-HGNs had a PEG shell of around 
5 nm (Fig. 1A). As shown in Fig. 1B, both NPs dispersions presented a characteristic surface 
plasmon resonance peak above 800 nm (NIR region), making them useful for optical 
hyperthermia applications (this peak is characteristic of spherical PEG-HGNs of 
approximately 40 nm). Remarkably, it is crucial to obtain NPs of this size and morphology 
to guarantee their potential application as optical hyperthermia absorbing moieties in the 
NIR region.8 Z-potential measurements gave a negative surface charge in HGNs (-16.38 ± 
2.72 mV) and PEG-HGNs (-16.56 ± 2.96 mV) at pH 7.  
B16-F10-exos characterization 
B16-F10-exos were spherical vesicles with a diameter of 95.1 ± 27.8 nm (Fig 2A) as 
expected from the literature.9,10 They presented a double lipidic membrane with a thickness 
 
of almost 10 nm (observed in TEM images from Fig 2A). Exosome diameter was also 
confirmed by NTA, revealing also a diameter of 159.7 ± 57.4 nm (Fig. 2B). Exosomes 
were negatively charged (zeta potential of -18.56 ± 1.93 mV in 10 mM KCl at pH 7) due to 
the phospholipid nature of the exosomal membranes.11 Fig. 2C shows the results of the 
Western Blot (WB) assays indicating that B16-F10-exos expressed a housekeeping gene (α-
actin), an exosomal membrane protein (CD9) and a citoplasmatic exosomal marker 
(TSG101). On the contrary, when using a non-exosomal protein (calnexin) no band 
was observed. These results confirm that B16-F10-exos correspond with exosomes 
rather than with other extracellular vesicles of different nature.12 
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Figure S1. TEM images of exosomes treated by the different physicochemical approaches 
in absence of NPs (incubation at room temperature with the presence or absence of saponin, 






Fig. S2. A) Representative TEM images obtained from exosomes released by untreated B16-
F10 cells, by manumycin A treated cells or by siRab27 transfected cells. B) Semiquantitative 
analysis of secreted exosomes released by untreated B16-F10 cells, by manumycin A treated 









Summary Adjusted P Value 
  Incubation R.T. with saponin (0.2 %) vs. Incubation R.T. ns 0.9988 
  Incubation R.T. with saponin (0.2 %) vs. Thermal shock I ns 0.9241 
  Incubation R.T. with saponin (0.2 %) vs. Thermal shock II ns 0.573 
  Incubation R.T. with saponin (0.2 %) vs. Sonication ns 0.9645 
  Incubation R.T. with saponin (0.2 %) vs. Electroporation * 0.0124 
  Incubation R.T. with saponin (0.2 %) vs. Incubation with B16-F10cells **** <0.0001 
  Incubation R.T. vs. Thermal shock I ns 0.7093 
  Incubation R.T. vs. Thermal shock II ns 0.8343 
  Incubation R.T. vs. Sonication ns 0.7993 
  Incubation R.T. vs. Electroporation * 0.0296 
  Incubation R.T. vs. Incubation with B16-F10cells **** <0.0001 
  Thermal shock I vs. Thermal shock II ns 0.1276 
  Thermal shock I vs. Sonication ns >0.9999 
  Thermal shock I vs. Electroporation ** 0.0018 
  Thermal shock I vs. Incubation with B16-F10cells **** <0.0001 
  Thermal shock II vs. Sonication ns 0.168 
  Thermal shock II vs. Electroporation ns 0.2706 
  Thermal shock II vs. Incubation with B16-F10cells **** <0.0001 
  Sonication vs. Electroporation ** 0.0024 
  Sonication vs. Incubation with B16-F10cells **** <0.0001 
  Electroporation vs. Incubation with B16-F10cells **** <0.0001 
Table S1. Statistical analysis of the encapsulation of NPs within exosomes. 
 
HGNs 24 h Summary Adjusted P Value 
Control vs. 0.5 mg/mL **** <0.0001 
Control vs. 0.250 mg/mL ** 0.0024 
Control vs. 0.125 mg/mL ns 0.355 
Control vs. 0.06 mg/mL ns 0.8128 
Control vs. 0.03 mg/mL ns 0.917 
Control vs. 0.015 mg/mL ns 0.8727 
Control vs. 0.006 mg/mL ns 0.6999 
PEG-HGNs 24 h Summary Adjusted P Value 
Control vs. 0.5 mg/mL ns 0.0813 
Control vs. 0.250 mg/mL ns 0.6189 
Control vs. 0.125 mg/mL ns 0.2749 
Control vs. 0.06 mg/mL ns 0.3113 
Control vs. 0.03 mg/mL ns 0.8098 
Control vs. 0.015 mg/mL ns 0.8757 
Control vs. 0.006 mg/mL ns 0.6958 
HGNs 48 h Summary Adjusted P Value 
Control vs. 0.5 mg/mL *** 0.0007 
Control vs. 0.250 mg/mL *** 0.0005 
Control vs. 0.125 mg/mL ns 0.1041 
 
Control vs. 0.06 mg/mL ns 0.695 
Control vs. 0.03 mg/mL ns 0.5105 
Control vs. 0.015 mg/mL ns 0.6599 
Control vs. 0.006 mg/mL ns 0.1819 
PEG-HGNs 48 h Summary Adjusted P Value 
Control vs. 0.5 mg/mL *** 0.0007 
Control vs. 0.250 mg/mL ** 0.0049 
Control vs. 0.125 mg/mL ns 0.0824 
Control vs. 0.06 mg/mL ns 0.206 
Control vs. 0.03 mg/mL ns 0.9997 
Control vs. 0.015 mg/mL ns 0.9997 
Control vs. 0.006 mg/mL ns 0.9995 
HGNs 72 h Summary Adjusted P Value 
Control vs. 0.5 mg/mL *** 0.0007 
Control vs. 0.250 mg/mL ** 0.0049 
Control vs. 0.125 mg/mL ns 0.0824 
Control vs. 0.06 mg/mL ns 0.206 
Control vs. 0.03 mg/mL ns 0.9997 
Control vs. 0.015 mg/mL ns 0.9997 
Control vs. 0.006 mg/mL ns 0.9995 
 
PEG-HGNs 72 h Summary Adjusted P Value 
Control vs. 0.5 mg/mL ns 0.622 
Control vs. 0.250 mg/mL ns 0.711 
Control vs. 0.125 mg/mL ns 0.9882 
Control vs. 0.06 mg/mL ns 0.992 
Control vs. 0.03 mg/mL ns >0.9999 
Control vs. 0.015 mg/mL ns >0.9999 
Control vs. 0.006 mg/mL ns 0.9995 















A) Summary Adjusted P 
Value 
Control vs. PEG-HGNs 24 h **** <0.0001 
Control vs. PEG-HGNs 48 h ns 0.9925 
Control vs. PEG-HGNs 72 h ns 0.8895 
Control vs. HGNs 24 h ns 0.9999 
Control vs. HGNs 48 h ns 0.9999 
Control vs. HGNs 72 h ns 0.9999 
 
B) Summary Adjusted P 
Value 
  PEG-HGNs 24 h vs. PEG-HGNs 48 h ** 0.0018 
  PEG-HGNs 24 h vs. PEG-HGNs 72 h ** 0.0029 
  PEG-HGNs 48 h vs. PEG-HGNs 72 h ns 0.9363 
 Summary Adjusted P 
Value 
  HGNs 24 h vs. HGNs 48 h ns 0.1067 
  HGNs 24 h vs. HGNs 72 h ns 0.6576 
  HGNs 48 h vs. HGNs 72 h ns 0.5691 
Table S3. Statistical analysis of the MP-AES experiment. A) Comparison of all the 
conditions with the untreated cells. B) Comparison of cells treated with one type of NPs at 
24, 48 and 72 hwith every other samples treated with these NPs at other time points 
 
 
Summary Adjusted P Value 
0 min ns >0.9999 
2 min ns 0.9745 
8 min ns 0.5989 
12 min ns 0.1282 
15 min ns 0.0915 
20 min ns 0.0726 
25 min * 0.0197 
30 min ** 0.0037 

















Summary Adjusted P 
Value 
Control vs. 2 h ns 0,2762 
  Control vs. 4 h ns 0,6152 
  Control vs. 6 h *** 0,0003 
  Control vs. 8 h **** <0,0001 
  Control vs. 24 h **** <0,0001 
  Control vs. 48 h **** <0,0001 
Table S5. Statistical analysis of exosPEG-HGNs inside cell cytoplasm from confocal 
images. 
 
 
